BRIEF REPORT

Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group of Tumors

James Huang, MD,* Usman Ahmad, MD,* Alberto Antonicelli, MD,‡ Ann Christine Catlin,¶
Wentao Fang, MD,# Daniel Gomez, MD,** Patrick Loehrer, MD,‡‡ Marco Lucchi, MD,§§
Edith Marom, MD,†† Andrew Nicholson, MD,‖‖ Enrico Ruffini, MD,¶¶ William Travis, MD,†
Paul Van Schil, MD,## Heather Wakelee, MD,*** Xiaopan Yao, PhD,§ Frank Detterbeck, MD‖ on behalf of
the International Thymic Malignancy Interest Group International Database Committee and Contributors†††

Background: Our knowledge of thymic malignancies has largely been derived from small, single-institution series. Recognition of the need for broad collaboration led to the creation of the International Thymic Malignancy Interest Group (ITMIG) and the development of a large, centralized database to advance knowledge of these rare tumors.

Methods: A multidisciplinary Database Committee was convened to define a common set of data elements a priori. Retrospective data were solicited from ITMIG members and collated using standardized fields. Patients with thymoma, thymic carcinoma, or thymic carcinoid were included.

Results: Over a 6-month period, 47 institutions spanning 15 countries contributed a total of 6097 cases (mean, 129 [range, 10–1209]). The sex distribution was equal for thymomas, but there was a greater proportion of men with thymic carcinoma and thymic carcinoid ($p < 0.0001$). Nearly all cases (99%) were treated surgically. WHO type B2 was the most frequent histologic classification among thymomas, whereas squamous was the most common among thymic carcinomas. In total, 38% of patients with thymoma had myasthenia gravis compared with less than or equal to 5% for thymic carcinoma and thymic carcinoid. Median overall survival was 18.9 years (95% confidence interval [CI], 17.4–20.3) for thymoma, 6.8 years (95% CI, 5.5–7.9) for thymic carcinoma, and 7.5 years (95% CI, 6.5–8.5) for thymic carcinoid.

Conclusions: The rapid creation of the ITMIG database demonstrates the feasibility of international collaboration for this rare set of malignancies and attests to the engagement of its membership. This database represents the largest collective data set ever assembled and provides an unprecedented resource for research of these tumors.

Key Words: Thymoma, Thymic carcinoma, Thymic carcinoid, Database, Thymic malignancies.

Departments of *Surgery and †Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; ‡Department of Surgery, §Yale Center of Analytical Science, and ‖Department of Thoracic Surgery, Yale University, New Haven, Connecticut; ¶Department of Research Computing, Purdue University, West Lafayette, Indiana; #Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai, China; Departments of **Radiation Oncology and ††Diagnostic Radiology, MD Anderson Cancer Center, Houston, Texas; ‡‡Department of Internal Medicine, Indiana University, Bloomington, Indiana; §§Department of Thoracic Surgery, University of Pisa, Pisa, Italy; ‖Department of Histopathology, Royal Brompton Hospital, London, UK; ¶¶Department of Thoracic Surgery, University of Torino, Torino, Italy; ##Department of Thoracic and Vascular Surgery, University Hospital of Antwerp, Antwerp, Belgium; and ***Department of Medicine, Stanford University, Stanford, California.
†††A list of the contributors is given in Appendix 1.

Thymic malignancies are uncommon tumors whose unusual behavior and association with immunologic derangements have long captivated clinicians. Few prospective studies have been conducted, and our knowledge is largely derived from small, dated series. The seminal report by Masaoka et al.,[1] whose eponymous classification was based on only 96 patients, appeared more than three decades ago. Given the rarity of these malignancies, meaningful advancement requires international collaboration.[2]

The International Thymic Malignancy Interest Group (ITMIG) arose from the recognition of this need.[3] One of its central priorities was the collection of worldwide data and the development of a centralized database. The precedent of the International Association for the Staging of Lung Cancer staging project provided a model for collaboration,[4] and the need for more data to inform the development of a formal staging classification served as a major driver for this project.[5]

This database was also intended as a resource for the investigation of clinical issues, including histology, treatment, prognosis, autoimmune disease, and second malignancies. Existing population-based registries are limited in their utility for addressing these specific questions,[6] and this effort was aimed at enriching data collection with greater detail. This article provides an overview of the ITMIG database, its contents, and the process behind its creation.

PATIENTS AND METHODS

The ITMIG Database Committee has broad representation, including surgery, medical oncology, radiation oncology,

radiology, pathology, and information technology across North America, Europe, and Asia. The committee was assigned the tasks of defining the relevant data elements and identifying a suitable provider to create the data infrastructure.

A collaboration between ITMIG and Purdue University created the data structure, using the HUBzero platform and the Purdue Cancer Center Engineering project.[7] This created an open-source, Health Insurance Portability and Accountability Act-compliant infrastructure with flexibility for future expansion as a centralized hub for scientific discourse among ITMIG members.

Existing retrospective data were collected from established institutional databases worldwide. A common set of data elements was defined in collaboration with the Japanese Association for Research of the Thymus, the European Society of Thoracic Surgeons, and the Chinese Association for Research of the Thymus (Supplemental Appendix 1, Supplemental Digital Content, http://links.lww.com/JTO/A637). The database includes patients diagnosed with thymoma, thymic carcinoma, or thymic carcinoid. To achieve consistency, the data elements build on the standard definitions developed by ITMIG,[8] the Masaoka or Masaoka-Koga stage classification systems,[1,9] the World Health Organization histologic classification,[10] and the Myasthenia Gravis Foundation of America classification of myasthenia gravis severity.[11]

Patient characteristics were compared using two-tailed *t* tests for continuous variables and χ^2 and Fisher's exact tests for categorical variables. Survival was measured from the first date of treatment to the date of death or last follow-up, and curves were generated using the Kaplan-Meier method.

RESULTS

From September 2012 to February 2013, a total of 6097 cases were submitted from 47 institutions across 15 countries spanning North America, South America, Europe, and Asia. The tasks of cleaning, standardization, clarification of missing or nonsensical entries, and aggregation of data were completed by August 2013. The contributing centers are listed in Table 1 and Figure 1. Institutions contributed a mean of 129 cases (range, 10–1209). Basic demographic characteristics are listed in Table 2. Most of the cases were diagnosed between 2000 and 2010. The mean age was similar among patients with thymoma, thymic carcinoma, and thymic carcinoid; however, whereas sex distribution was equal among patients with thymoma, there was a greater proportion of men among those with thymic carcinoma ($p < 0.0001$) and thymic carcinoid ($p < 0.0001$).

Histologic Classification

The histologic distribution is listed in Table 3; B2 was the most common histologic classification reported. Among patients with thymic carcinoma, squamous was the most common histologic classification reported. The distribution of Masaoka stage is listed in Table 4. In some cases, Masaoka (or Masaoka-Koga) stage was provided without further subdivision into A or B subcategories (stages II and IV). A majority had early-stage tumors (Masaoka I or II), but a substantial number of stage III ($n = 1167$) and IV ($n = 673$) cases were also captured.

TABLE 1. Contributing Institutions by Country

Country	Institution(s)
Argentina	Alexander Fleming Institute, Maria Ferrer Institute
Belgium	Antwerp University, University Hospitals Leuven
China	Beijing Cancer Hospital, Henan Cancer Hospital, Shanghai Chest Hospital, Shanghai Pulmonary Disease Hospital, Sichuan Cancer Hospital, Tianjin Cancer Hospital
Denmark	Rigshospitalet University Hospital
France	Louis Pradel Hospital
Germany	Klinik Schillerhoehe, Mannheim University
Greece	AHEPA University
Italy	Hospital Riuniti, Ancona; Regina Elena National Cancer Institute, Rome; S. Croce e Carle Hospital, Cuneo; University of Catania; University of Napoli Federico II; University of Padua; University of Pisa; University of Torino
Korea	Gangnam Severance Hospital, Seoul National Hospital, Severance Hospital
Netherlands	Maastricht University
Romania	Fundeni Clinical Institute Bucharest
Spain	Hospital Mutua de Terrassa
Turkey	Istanbul Medical University
United Kingdom	Birmingham Heartlands Hospital, Guy's and St. Thomas Hospital, Royal Brompton & Harefield
United States	Fox Chase, Hackensack University Medical Center, Indiana University, Massachusetts General Hospital, Mayo Clinic, MD Anderson Cancer Center, Memorial Sloan Kettering, Oregon Health and Science University, Penn Presbyterian Medical Center, Stanford University, Swedish Medical Center, University of Chicago, Yale University

Autoimmune Disease

Autoimmune disease was reported in one-third of all patients with thymic malignancies and was primarily limited to patients with thymoma (Table 5). In total, nearly 38% of patients with thymoma had myasthenia gravis. Other paraneoplastic syndromes, such as hypogammaglobulinemia and red cell aplasia, were exceedingly rare, with each representing less than 1% of thymoma cases. Autoimmune disease was also rare among patients with thymic carcinoma and thymic carcinoid, with nearly all involving myasthenia gravis ($n = 36$).

Treatment

The vast majority of submitted cases were treated at initial diagnosis with surgery as primary therapy (Fig. 2). Adjuvant radiotherapy was administered to 1664 patients (42%), and a minority of patients received neoadjuvant therapy, either chemotherapy (11%) or radiotherapy (2%). Less than 1% of cases received palliative chemotherapy ($n = 27$) or radiotherapy ($n = 7$) only.

Outcomes

Vital status was available for 4821 cases (79%), with 904 deaths (19%). Recurrence status was available for 4101 cases (67%), 715 of whom experienced relapse (17%). Information on cause of death was available for 526 cases: 325 (62%) died

**INTERNATIONAL** Thymic Malignancy Interest Group:
Database Participants

FIGURE 1. Geographic distribution of contributing centers to the ITMIG database.

TABLE 2. Demographic Characteristics

Characteristic	All	Thymoma	Thymic Carcinoma	Thymic Carcinoid
Total	6097	4918	848	160
Age, years, mean (SD)	54.0 (14)	53.9 (14)	55.2 (14)	54.7 (12.5)
Male, no. (%)	3088 (51)	2365 (48)	507 (60)	121 (76)

TABLE 3. Distribution of WHO Histologic Profiles

Diagnosis, WHO Profile	No. (%)
Thymoma	4529
A	497 (11)
AB	1026 (23)
B1	737 (16)
B2	1273 (28)
B3	894 (20)
Micronodular	87 (2)
Metaplastic	15 (<1)
Thymic carcinoma	602
Squamous	481 (80)
Lymphoepithelioma-like	36 (6)
Basaloid	19 (3)
Undifferentiated	16 (3)
Sarcomatoid	12 (2)
Adenocarcinoma	11 (2)
Mucoepidermoid	9 (1)
Clear cell	8 (1)
Other	10 (2)

TABLE 4. Distribution of Masaoka Stage

Stage	No. (%)
I	1582 (32)
II	424 (9)
IIa	581 (12)
IIb	560 (11)
III	1167 (23)
IV	45 (1)
IVa	371 (7)
IVb	257 (5)
Total	4987

II and IV are cases submitted with a and b subclassification.

TABLE 5. Paraneoplastic Syndromes

Syndrome	Thymoma	Thymic Carcinoma	Thymic Carcinoid
None	2623 (61)	607 (95)	119 (96)
Myasthenia gravis	1634 (38)	31 (5)	5 (4)
Hypogammaglobulinemia	13 (<1)	1 (<1)	0 (0)
Red cell aplasia	37 (1)	1 (<1)	0 (0)
Not available	611 (14)	208 (33)	36 (29)

Data are no. (%).

calculable for 4009 patients. Median survival was 18.9 years (95% confidence interval [CI], 17.4–20.3) for patients with thymoma, 6.8 years (95% CI, 5.5–7.9) for patients with thymic carcinoma, and 7.5 years (95% CI, 6.5–8.5) for patients with thymic carcinoid (Fig. 4).

of tumor-related causes (including myasthenia-related complications), 36 (7%) died of treatment-related causes, and 165 (31%) died of nontumor-related causes (Fig. 3). Survival was

DISCUSSION

The ITMIG International Database represents the largest data set of thymic malignancies ever compiled and

FIGURE 2. Treatment modalities.

provides an unprecedented resource for inquiry. To stimulate research, this article provides investigators with an overview of the contents of the database, including the demographic characteristics, management, and outcomes of these patients. The number of institutions and cases speaks to the depth of

interest and feasibility of international collaboration to study these orphan diseases. That the project was accomplished in less than 6 months is a testament to the broad support that has propelled the growth of ITMIG.[3]

The prolonged survival observed appears to suggest a better prognosis than previously demonstrated. Even among the more aggressive tumors, such as thymic carcinomas and carcinoids, median survival approached 7 years. The largest previous experience, of 1320 cases from Japan, noted a median survival of just over 5 years.[12] Whether the difference in survival is a function of better treatment, diagnosis, or data remains unknown. Our findings support the notion that refocusing on recurrence instead of survival may be more clinically useful.[8]

Whether these outcomes should justify more-extensive treatment or support less-aggressive strategies is unclear. Small series have demonstrated the feasibility of extended resections[13]; yet, nonsurgical approaches have also led to prolonged survival.[14] Nevertheless, of the patients with known cause of death, two-thirds ultimately died of disease-related causes, suggesting there is still room for improvement.

Although the data set contains few nonsurgical cases, a substantial number received multimodality treatment,


FIGURE 3. Causes of death (*n* = 526).

FIGURE 4. Overall survival by tumor type.

including adjuvant radiation. The utility of this strategy remains controversial, and a recent meta-analysis suggested no benefit.[15] The inclusion of over 1600 cases with adjuvant radiation in the database presents a unique opportunity to study this question.

The incidence of myasthenia gravis associated with thymoma in our analysis (38%) was somewhat higher than in other reports, such as 25% among 1089 Japanese patients with thymoma.[12] However, less than 1% of our patients had hypogammaglobulinemia or red cell aplasia. These less common autoimmune disorders may be underreported in the ITMIG database.

Selection bias and other limitations are inherent in the ITMIG database. The data on patients managed nonsurgically are limited, and information on patients at the margins—the metastatic, medically inoperable, and unresectable patients—is lacking. Missing data are inevitable in any large but voluntary collaborative efforts. Centralized pathologic review was not feasible in this retrospective setting, but our data reflect histologic classification in actual practice.

The ITMIG database offers investigators a large and rich data set for research. Contributors to the database are invited to submit research proposals to ITMIG. Approved projects will be conducted in coordination with a statistical core in ITMIG to facilitate data selection and analysis. The first series of analyses is nearing completion. In keeping with the collaborative culture of ITMIG, we encourage investigators posing similar questions to join together.

The ITMIG International Database is only one part of the foundation for collaborative research in thymic malignancies. It provides the basis for the first official stage classification system, a fundamental necessity for further progress.[5] Insights gained from the retrospective analysis will clarify our knowledge gaps and inform further queries. Accrual to a more detailed prospective database is now under way, and innovative approaches such as Bayesian analysis are being explored. Since the inception of ITMIG in 2010, major strides have been made in developing infrastructure across international boundaries. It is the hope of ITMIG that the International Database will provide another step toward advancing our understanding of these orphan diseases.

APPENDIX 1: LIST OF ITMIG INTERNATIONAL DATABASE CONTRIBUTORS

Argentina: Moises Rosenberg, Alexander Fleming Institute and Maria Ferrer Institute.

Belgium: Paul Van Schil, Antwerp University; Hans Van Veer, University Hospitals Leuven.

China: Wentao Fang, Shanghai Chest Hospital; Gu Zhi Tao, Shanghai Chest Hospital, Henan Cancer Hospital, Tianjin Cancer Hospital, Beijing Cancer Hospital, Shanghai Pulmonary Disease Hospital, and Sichuan Cancer Hospital.

Denmark: Kristoffer Staal Rohrberg and Gedske Daugaard, Rigshospitalet University Hospital.

France: Nicolas Girard, Louis Pradel Hospital.

Germany: Philipp Strobel and Alexander Marx, Mannheim University; Martin Kimmich, Klinik Schillerhoehe.

Greece: Christophoros N. Foroulis, AHEPA University.

Italy: Salvatore Saita, Azienda Ospedaliero-Universitaria Policlinico V. Emanuele; Luca Bertolaccini, Azienda Ospedaliera S. Croce e Carle; Mirella Marino, Regina Elena National Cancer Institute; Giovanella Palmieri and Carlo Buonerba, Universita' degli Studi di Napoli Federico II; Giuseppe Marulli, University of Padua; Marco Lucchi and Anna De Rosa, University of Pisa; Alessandro Brunelli, Ospedali Riuniti, Ancona, Italy.

Korea: Seok Jin Haam, Gangnam Severance Hospital; Mi Kyung Bae, Severance Hospital; In Kyu Park, Seoul National Hospital.

Netherlands: Marlies Keijzers, Maastricht University.

Romania: Victor Nicolae Tomulescu, Fundeni Clinical Institute, Bucharest.

Spain: Sergi Call Caja and Juan Carlos Trujillo, Hospital Mutua de Terrassa.

Turkey: Alper Toker and Saut Erus, Istanbul Medical University.

United Kingdom: Maninder Singh Kalkat, Birmingham Heartlands Hospital; Andrew G. Nicholson and Eric Lim, Royal Brompton Hospital & Harefield NHS Foundation Trust; Loic Lang-lazdunski and Andrea Billé, Guy's and St Thomas Hospital.

United States: Frank Detterbeck, Yale University; Daniel R. Gomez and Edith Marom, MD Anderson Cancer Center; Heather Wakelee, Stanford University; Eric Vallieres, Swedish Medical Center; Walter Scott and Stacey Su, Fox Chase; Bernard Park and Jennifer Marks, Hackensack University Medical Center; Sami Khella, Penn Presbyterian Medical Center; Robert Shen, Mayo Clinic; James Huang, Memorial Sloan Kettering Cancer Center; Cameron Wright, Massachusetts General Hospital; Mark Ferguson, University of Chicago; Patrick Loehrer, Indiana University; Jesse Wagner, Oregon Health and Science University.

REFERENCES

1. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. *Cancer* 1981;48:2485–2492.
2. Thomas PA. The need for organization and collaboration: establishing a thymoma registry. *Thorac Surg Clin* 2011;21:131–134, viii.
3. Detterbeck F. International thymic malignancies interest group: a way forward. *J Thorac Oncol* 2010;5(10 Suppl 4):S365–S370.
4. Goldstraw P, Crowley J, Chansky K, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. *J Thorac Oncol* 2007;2:706–714.
5. Detterbeck FC, Asamura H, Crowley J, et al.; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain. The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies. *J Thorac Oncol* 2013;8:1467–1473.
6. Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. *Int J Cancer* 2003;105:546–551.
7. McLennan M, Kennell R. HUBzero: a platform for dissemination and collaboration in computational science and engineering. *Comput Sci Eng* 2010;12:48–52.
8. Huang J, Detterbeck FC, Wang Z, Loehrer PJ Sr. Standard outcome measures for thymic malignancies. *J Thorac Oncol* 2010;5:2017–2023.
9. Koga K, Matsuno Y, Noguchi M, et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. *Pathol Int* 1994;44:359–367.

10. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. *Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart*. Lyon: IARC Press, 2004.

11. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. *Ann Thorac Surg* 2000;70:327–334.

12. Kondo K, Monden Y. Lymphogenous and hematogenous metastasis of thymic epithelial tumors. *Ann Thorac Surg* 2003;76:1859–1864.

13. Huang J, Rizk NP, Travis WD, et al. Feasibility of multimodality therapy including extended resections in stage IVA thymoma. *J Thorac Cardiovasc Surg* 2007;134:1477–1483.

14. Loehrer PJ Sr, Chen M, Kim K, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. *J Clin Oncol* 1997;15:3093–3099.

15. Korst RJ, Kansler AL, Christos PJ, Mandal S. Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. *Ann Thorac Surg* 2009;87:1641–1647.